查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1629250

神經母細胞瘤藥物市場，按給藥途徑、類型、最終用戶、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Neuroblastoma Drugs Market, By Route of Administration, By Type, By End-user, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023 年神經母細胞瘤藥物市場規模為 8.155 億美元，2024 年至 2032 年複合年成長率為 5.80%。

神經母細胞瘤藥物市場-市場動態

神經母細胞瘤的發生率上升

推動神經母細胞瘤藥物市場擴張的主要驅動力之一是該疾病發生率的上升。近年來，神經母細胞瘤的診斷顯著增加，尤其是在青少年族群。由於這種發病率趨勢，對複雜且成功的治療策略的需求增加了。隨著診斷能力的增強和認知的提高，發現了更多病例，鼓勵製藥公司和研究人員加強開發新型神經母細胞瘤藥物，這支持了神經母細胞瘤藥物市場的擴張。

神經母細胞瘤藥物市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球神經母細胞瘤藥物市場在預測期內（2024-2032）每年將以 5.80% 左右的複合年成長率成長

根據給藥途徑細分，預計注射劑類別將在 2023 年佔據最大市場佔有率

根據最終用戶細分，醫院是 2023 年的領先細分市場

按地區分類，北美是 2023 年的主要收入來源

神經母細胞瘤藥物市場-細分分析：

全球神經母細胞瘤藥物市場根據給藥途徑、類型、最終用戶和地區進行細分。

根據給藥途徑，神經母細胞瘤藥物市場分為口服和注射。 2023年，注射劑類別由於其有效性、簡單性以及精確施用神經母細胞瘤藥物劑量的能力，在全球神經母細胞瘤藥物市場中佔據主導地位。注射製劑進一步促進了該類別的成長，它提供了可靠且直接的給藥途徑，確保了快速吸收和生物利用度，這在兒科腫瘤學中尤其重要。

按類型分類，市場分為化療、免疫治療、骨髓移植、類維生素A治療、手術等。由於知識的不斷成長和研究的發展，免疫療法有望獲得更持久和有效的結果，預計在神經母細胞瘤藥物市場預測期內將創下最高的年複合成長率（CAGR）。免疫療法目前佔據全球最大的市場。此外，由於持續的臨床試驗和合作努力，該領域正在不斷成長，增強了免疫療法的勢頭，並將其確立為不斷變化的神經母細胞瘤治療領域的一種改變遊戲規則的策略。

神經母細胞瘤藥物市場 - 地理洞察

從地理來看，神經母細胞瘤藥物市場廣泛分佈於北美、拉丁美洲、歐洲、亞太地區、中東和非洲地區。這些區域根據開展業務的國家進一步分類。

2023 年，北美在神經母細胞瘤藥物市場佔有率中佔據最大佔有率。據估計，2015年美國在癌症治療上的支出超過1,900億美元，預計到2020年這一數字將增加超過2,000億美元。 。隨著越來越多的人接受化療和藥物治療以預防更多疾病併發症，預計該行業將會成長。

歐洲的神經母細胞瘤藥物市場預計將佔據第二大佔有率。兒童癌症發生率上升和癌症治療費用上升是推動市場擴張的主要因素。此外，由於抗 GD2 具有位點特異性活性且對身體缺乏細胞毒性作用，因此抗 GD2 作為第一種獲得許可用於治療神經母細胞瘤的藥物，需求量巨大。此外，該地區不斷成長的嬰兒人口以及神經母細胞瘤尖端創新療法的開發正在推動神經母細胞瘤藥物市場的擴張。此外，對神經母細胞瘤診斷和治療的更多了解使得我們可以專注於新的腫瘤靶點，以利用細胞介導的免疫療法開發癌症藥物。

神經母細胞瘤藥物市場-競爭格局：

在全球和區域範圍內營運的各種競爭對手的存在，例如Y-mabs Therapeutics, Inc.、Bristol-Myers Squibb Company、MacroGenics Inc.、AstraZeneca plc、Eli Lilly and Company 等，是造成高估值的主要原因。各種各樣的業務都對市場的整體動態做出了貢獻，從而定義了競爭格局。現有產業巨頭、新進業者和專業解決方案提供者之間對市場佔有率的競爭是造成這種碎片化的原因。神經母細胞瘤藥物市場上的主要參與者使用收購、合作、協議和產品批准作為擴大其產品組合的重要開發策略。例如，根據商業階段生物製藥企業 Y-mAbs Therapeutics, Inc. 的說法，2023 年 5 月，巴西衛生監管局批准了 DANYELZA (naxitamab-gqgk) 40mg/10mL 注射液的商業化。在巴西，Y-mAbs 的合作夥伴 Adium Pharma SA 將銷售 DANYELZA。

最新進展：

2023 年2 月：根據商業階段生物製藥新創公司Y-mAbs Therapeutics, Inc. 發布的一份聲明，歐洲藥品管理局批准了擬議的naxitamab 兒科研究計劃。這一結論。 PIP 所針對的適應症，即復發/難治性高風險神經母細胞瘤以及骨肉瘤，是 Y-mAb 正在開發 naxitamab 的疾病。

目錄

第1章：神經母細胞瘤藥物市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 依給藥途徑分類的神經母細胞瘤藥物市場片段
    • 按類型分類的神經母細胞瘤藥物市場片段
    • 最終使用者的神經母細胞瘤藥物市場片段
    • 按國家/地區分類的神經母細胞瘤藥物市場片段
    • 按地區分類的神經母細胞瘤藥物市場片段
  • 競爭洞察

第 3 章：神經母細胞瘤藥物主要市場趨勢

  • 神經母細胞瘤藥物市場促進因素
    • 市場促進因素的影響分析
  • 神經母細胞瘤藥物市場限制
    • 市場限制影響分析
  • 神經母細胞瘤藥物市場機會
  • 神經母細胞瘤藥物市場未來趨勢

第 4 章：神經母細胞瘤藥物產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：神經母細胞瘤藥物市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：神經母細胞瘤藥物市場格局

  • 2023 年神經母細胞瘤藥物市佔率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：神經母細胞瘤藥物市場 - 依給藥途徑

  • 概述
    • 按給藥途徑分類的細分市場佔有率分析
    • 口服
    • 可注射

第 8 章：神經母細胞瘤藥物市場 - 按類型

  • 概述
    • 按類型分類的細分市場佔有率分析
    • 化療
    • 免疫療法
    • 骨髓移植
    • 類維生素A療法
    • 手術
    • 其他

第 9 章：神經母細胞瘤藥物市場 - 按最終用戶

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 醫院
    • 居家護理
    • 專科診所
    • 其他

第 10 章：神經母細胞瘤藥物市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美神經母細胞瘤藥物主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模與預測（按管理途徑）
    • 北美市場規模和預測（按類型）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲神經母細胞瘤藥物主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模與預測（按管理途徑）
    • 歐洲市場規模與預測（按類型）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區神經母細胞瘤藥物主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模與預測（依管理途徑）
    • 亞太地區市場規模與預測（按類型）
    • 亞太地區市場規模和預測（按最終用戶）
    • 印度
    • 中國
    • 韓國
    • 日本
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲神經母細胞瘤藥物主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按管理途徑）
    • 拉丁美洲市場規模與預測（按類型）
    • 拉丁美洲市場規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲神經母細胞瘤藥物主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按管理途徑）
    • 中東和非洲市場規模及預測（按類型）
    • 中東和非洲市場規模和預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析 - 神經母細胞瘤藥物產業

  • 競爭儀表板
  • 公司簡介
    • Y-mabs Therapeutics, Inc.
    • Bristol-Myers Squibb Company
    • MacroGenics Inc.
    • AstraZeneca plc
    • Eli Lilly and Company
    • Recordati Group
    • Cellectar Biosciences, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • United Therapeutics Corporation
    • Others

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4423

REPORT HIGHLIGHT

Neuroblastoma Drugs Market size was valued at USD 815.5 Million in 2023, expanding at a CAGR of 5.80% from 2024 to 2032.

The most prevalent kind of cancer among newborns is neuroblastoma. The sympathetic nervous system's embryonic malignancy, which arises from the neuroblasts, is what causes the cancer. The malignancy spreads to the spinal cord, chest, or adrenal nerve tissues. Neuroblastoma is diagnosed before the age of five in over 90% of cases. In rare instances, prenatal ultrasounds may reveal the malignancy. The increased incidence of neuroblastoma and childhood cancer are the main causes of the neuroblastoma drug market's expansion. According to estimates, as of 2023, over 700 children in the US will receive a neuroblastoma diagnosis annually. Additionally, the neuroblastoma drugs market is expected to develop as a result of people's increased awareness of cancer diagnosis and treatment. In the upcoming years, it is anticipated that the growing number of incident instances that are age- and gender-specific will spur industry expansion.

Neuroblastoma Drugs Market- Market Dynamics

Rising Incidence of Neuroblastoma

One of the main driver driving the market expansion for neuroblastoma drugs is the rise in the disease's occurrence. Neuroblastoma diagnoses have increased noticeably in recent years, especially in juvenile populations. The need for sophisticated and successful therapeutic strategies has increased as a result of this incidence trend. Pharmaceutical firms and researchers are encouraged to step up their efforts in creating novel neuroblastoma medications as more cases are discovered due to enhanced diagnostic capabilities and more awareness, which supports the neuroblastoma drug market's expansion.

Neuroblastoma Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global Neuroblastoma Drugs Market is estimated to grow annually at a CAGR of around 5.80% over the forecast period (2024-2032)

Based on the route of administration segmentation, the injectable category was predicted to show maximum market share in the year 2023

Based on end-user segmentation, the hospitals were the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Neuroblastoma Drugs Market- Segmentation Analysis:

The Global Neuroblastoma Drugs Market is segmented on the basis of Route of Administration, Type, End-user, and Region.

Based on the route of administration, the neuroblastoma drugs market is segregated into Oral and Injectable. In 2023, the injectable category held a dominant market position in the worldwide neuroblastoma drugs market due to its effectiveness, ease, and capacity to administer precise amounts of neuroblastoma pharmaceuticals. Further bolstering the category growth are injectable formulations, which provide a dependable and straightforward administration route, guaranteeing quick absorption and bioavailability-particularly important in pediatric oncology.

By type, the market is divided into Chemotherapy, Immunotherapy, Bone Marrow Transplantation, Retinoid therapy, Surgery, and Others. Due to growing knowledge and research developments, immunotherapy shows promise for more lasting and effective results, and it is anticipated to record the highest compound annual growth rate (CAGR) during the neuroblastoma drugs market forecast period. Immunotherapy currently holds the largest market share worldwide. Furthermore, the segment is growing as a result of continuous clinical trials and cooperative efforts that strengthen immunotherapy's momentum and establish it as a game-changing strategy in the changing field of neuroblastoma treatment.

Neuroblastoma Drugs Market- Geographical Insights

Geographically, the Neuroblastoma Drugs Market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

North America held the greatest market share for neuroblastoma drugs in 2023. This increase is ascribed to both the rise of neuroblastoma cases and the development of technologically advanced medications. According to estimates, the United States spent more than USD 190 billion on cancer treatment in 2015, and that amount is expected to rise to over USD 200 billion in 2020. Additionally, the neuroblastoma drugs market is expanding due to rising healthcare sector spending and the approval of orphan drugs for the neuroblastoma treatment. The industry is expected to rise as more people receive chemotherapy and medication therapies to prevent more complications from the illness.

The market for neuroblastoma drugs in Europe is anticipated to hold the second-largest share. The rising incidence of childhood cancer and rising cancer treatment costs are the main factors driving the market's expansion. Additionally, due to its site-specific activity and lack of cytotoxic effects on the body, anti-GD2, the first medication licensed for the treatment of neuroblastoma, is seeing tremendous demand. Furthermore, the region's growing infant population and the creation of cutting-edge, innovative treatments for neuroblastoma are driving the neuroblastoma drugs market expansion. In addition, greater knowledge about neuroblastoma diagnosis and treatment has made it possible to concentrate on novel tumour targets for the development of cancer medications using cell-mediated immunotherapy.

Neuroblastoma Drugs Market- Competitive Landscape:

The presence of various competitors operating on a worldwide and regional scale, such as Y-mabs Therapeutics, Inc., Bristol-Myers Squibb Company, MacroGenics Inc., AstraZeneca plc, Eli Lilly and Company, and others are the main reason for the high degree of fragmentation in the neuroblastoma drugs market. A wide range of businesses that each contribute to the overall dynamics of the market defines the competitive landscape. The competition for market share among existing industry giants, newcomers, and specialist solution providers is the cause of this fragmentation. The market for neuroblastoma drugs has seen major players use acquisition, collaboration, agreement, and product approval as important developmental tactics to expand their product portfolio. For instance, in May 2023, The Brazilian Health Regulatory Agency approved the commercialization of DANYELZA (naxitamab-gqgk) 40mg/10mL injection, according to Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical business. In Brazil, Adium Pharma S.A., a partner of Y-mAbs, will sell DANYELZA.

Recent Developments:

February 2023: The European Medicines Agency approved the proposed pediatric investigation plan for naxitamab, according to a statement released by commercial-stage biopharmaceutical startup Y-mAbs Therapeutics, Inc. The Pediatric Committee expressed a favourable judgment, which led to the conclusion. The indication addressed by the PIP, relapsed/refractory high-risk neuroblastoma, as well as osteosarcoma, are the conditions for which Y-mAbs is developing naxitamab.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEUROBLASTOMA DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Y-mabs Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • MacroGenics Inc.
  • AstraZeneca plc
  • Eli Lilly and Company
  • Recordati Group
  • Cellectar Biosciences, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • United Therapeutics Corporation
  • Others

GLOBAL NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable

GLOBAL NEUROBLASTOMA DRUGS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Chemotherapy
  • Immunotherapy
  • Bone Marrow Transplantation
  • Retinoid therapy
  • Surgery
  • Others

GLOBAL NEUROBLASTOMA DRUGS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Homecare
  • Speciality Clinics
  • Other

GLOBAL NEUROBLASTOMA DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Neuroblastoma Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Neuroblastoma Drugs Market Snippet by Route of Administration
    • 2.1.2. Neuroblastoma Drugs Market Snippet by Type
    • 2.1.3. Neuroblastoma Drugs Market Snippet by End-user
    • 2.1.4. Neuroblastoma Drugs Market Snippet by Country
    • 2.1.5. Neuroblastoma Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Neuroblastoma Drugs Key Market Trends

  • 3.1. Neuroblastoma Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Neuroblastoma Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Neuroblastoma Drugs Market Opportunities
  • 3.4. Neuroblastoma Drugs Market Future Trends

4. Neuroblastoma Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Neuroblastoma Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Neuroblastoma Drugs Market Landscape

  • 6.1. Neuroblastoma Drugs Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Neuroblastoma Drugs Market - By Route of Administration

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 7.1.2. Oral
    • 7.1.3. Injectable

8. Neuroblastoma Drugs Market - By Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 8.1.2. Chemotherapy
    • 8.1.3. Immunotherapy
    • 8.1.4. Bone Marrow Transplantation
    • 8.1.5. Retinoid therapy
    • 8.1.6. Surgery
    • 8.1.7. Others

9. Neuroblastoma Drugs Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Homecare
    • 9.1.4. Speciality Clinics
    • 9.1.5. Others

10. Neuroblastoma Drugs Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Neuroblastoma Drugs Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Neuroblastoma Drugs Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.8. France
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.4. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.9. Italy
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.4. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.10. Spain
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.4. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.11. United Kingdom
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.12. Russia
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.13. Netherlands
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.14. Sweden
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.2. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Neuroblastoma Drugs Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.9. South Korea
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.4. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.10. Japan
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.4. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Neuroblastoma Drugs Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Neuroblastoma Drugs Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Neuroblastoma Drugs Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Y-mabs Therapeutics, Inc.
    • 11.2.2. Bristol-Myers Squibb Company
    • 11.2.3. MacroGenics Inc.
    • 11.2.4. AstraZeneca plc
    • 11.2.5. Eli Lilly and Company
    • 11.2.6. Recordati Group
    • 11.2.7. Cellectar Biosciences, Inc.
    • 11.2.8. Teva Pharmaceutical Industries Ltd.
    • 11.2.9. Pfizer Inc.
    • 11.2.10. United Therapeutics Corporation
    • 11.2.11. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us